Form 4: Zenas BioPharma Executive Acquires Stock Options
SEC Form 4 Filing
Orlando Oliveira, Chief Commercial Officer of Zenas BioPharma, acquired stock options for 410,000 shares of common stock on September 12, 2024.
Summary
- On September 12, 2024, Orlando Oliveira, the Chief Commercial Officer of Zenas BioPharma, acquired stock options for 410,000 shares of the company's common stock.
- The exercise price of these options is $17.
- The options vest over a period of 4 years, with 25% vesting on July 1, 2025, and the remainder vesting in equal monthly installments over the following 36 months, contingent upon continued service.
- The options expire on September 11, 2034.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard executive compensation disclosure.
Future Outlook
The vesting schedule suggests a commitment from the executive to remain with the company for at least four years.
Industry Context
Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of shareholders, potentially incentivizing value creation.
Key Dates
| Date | Description |
|---|---|
| 09/12/2024 | Date of the stock option grant. |
| 07/01/2025 | First vesting date for 25% of the options. |
| 09/11/2034 | Expiration date of the stock options. |
| 09/16/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.